Show simple item record

dc.contributor.authorThomson, David J
dc.contributor.authorYang, H
dc.contributor.authorBaines, H
dc.contributor.authorMiles, E
dc.contributor.authorBolton, S
dc.contributor.authorWest, Catharine M L
dc.contributor.authorSlevin, Nicholas J
dc.date.accessioned2014-04-17T13:55:08Z
dc.date.available2014-04-17T13:55:08Z
dc.date.issued2014-03-27
dc.identifier.citationNIMRAD - A phase III trial to investigate the use of Nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. 2014: Clin Oncolen
dc.identifier.issn1433-2981
dc.identifier.pmid24685344
dc.identifier.doi10.1016/j.clon.2014.03.003
dc.identifier.urihttp://hdl.handle.net/10541/315919
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Clinical oncology (Royal College of Radiologists (Great Britain))en
dc.titleNIMRAD - A Phase III trial to investigate the use of Nimorazole hypoxia modification with Intensity-modulated radiotherapy in head and neck cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalClinical Oncologyen


Files in this item

This item appears in the following Collection(s)

Show simple item record